BIASIOLO, ALESSANDRA
 Distribuzione geografica
Continente #
NA - Nord America 7.303
AS - Asia 3.397
EU - Europa 2.257
AF - Africa 865
SA - Sud America 801
OC - Oceania 84
Continente sconosciuto - Info sul continente non disponibili 34
Totale 14.741
Nazione #
US - Stati Uniti d'America 6.873
SG - Singapore 1.221
CN - Cina 731
BR - Brasile 485
HK - Hong Kong 366
IT - Italia 323
DE - Germania 298
VN - Vietnam 238
FI - Finlandia 234
SE - Svezia 166
PL - Polonia 142
UA - Ucraina 113
GB - Regno Unito 108
RU - Federazione Russa 87
IN - India 86
FR - Francia 82
NL - Olanda 65
AT - Austria 53
AR - Argentina 47
EC - Ecuador 45
JP - Giappone 39
MX - Messico 39
VE - Venezuela 38
LC - Santa Lucia 37
MA - Marocco 37
CZ - Repubblica Ceca 36
ES - Italia 36
PY - Paraguay 35
TR - Turchia 34
KR - Corea 33
AL - Albania 32
CO - Colombia 32
IE - Irlanda 32
YT - Mayotte 32
ZA - Sudafrica 31
AO - Angola 30
CA - Canada 30
JM - Giamaica 30
PE - Perù 30
ID - Indonesia 29
CI - Costa d'Avorio 28
CY - Cipro 28
EG - Egitto 28
JO - Giordania 28
SA - Arabia Saudita 28
TN - Tunisia 28
AZ - Azerbaigian 27
LY - Libia 27
PH - Filippine 27
UY - Uruguay 27
AE - Emirati Arabi Uniti 26
ET - Etiopia 26
MN - Mongolia 26
MR - Mauritania 26
MW - Malawi 26
UZ - Uzbekistan 26
BE - Belgio 25
BZ - Belize 25
IQ - Iraq 25
KG - Kirghizistan 25
PK - Pakistan 25
BF - Burkina Faso 24
IR - Iran 24
IS - Islanda 24
LA - Repubblica Popolare Democratica del Laos 24
ME - Montenegro 24
ML - Mali 24
NP - Nepal 24
SK - Slovacchia (Repubblica Slovacca) 24
CU - Cuba 23
HR - Croazia 23
MK - Macedonia 23
CL - Cile 22
CR - Costa Rica 22
GF - Guiana Francese 22
GT - Guatemala 22
IL - Israele 22
LB - Libano 22
MY - Malesia 22
PT - Portogallo 22
RO - Romania 22
CG - Congo 21
CV - Capo Verde 21
DZ - Algeria 21
GA - Gabon 21
GH - Ghana 21
HN - Honduras 21
NO - Norvegia 21
PA - Panama 21
SD - Sudan 21
TT - Trinidad e Tobago 21
TW - Taiwan 21
BB - Barbados 20
BD - Bangladesh 20
CM - Camerun 20
CW - ???statistics.table.value.countryCode.CW??? 20
GN - Guinea 20
MG - Madagascar 20
SN - Senegal 20
TH - Thailandia 20
Totale 13.842
Città #
Fairfield 816
Singapore 686
Ashburn 634
Chandler 579
Jacksonville 509
Woodbridge 485
Houston 427
Wilmington 347
Hong Kong 345
Cambridge 330
Ann Arbor 310
Seattle 290
Boardman 177
Beijing 172
Princeton 169
Santa Clara 157
Bytom 112
Helsinki 101
Padova 96
San Diego 94
Nanjing 85
Des Moines 75
Medford 73
Los Angeles 72
Munich 71
Ho Chi Minh City 66
Roxbury 63
Dong Ket 54
Dearborn 45
Guangzhou 42
Hanoi 42
São Paulo 38
Pune 36
Castries 35
Shenyang 35
Hefei 34
Chicago 31
Milan 30
New York 29
Nuremberg 29
Abidjan 28
Amman 28
Turku 28
Vienna 27
Bishkek 25
Changsha 25
Nouakchott 25
Tokyo 25
Ulan Bator 25
Baku 24
Hebei 24
Jinan 24
Luanda 24
Nanchang 24
Bamako 23
London 23
Dublin 22
Havana 22
Montevideo 22
Tashkent 22
Buffalo 21
Libreville 21
Podgorica 21
Falls Church 20
Kingston 20
Panama City 20
Accra 19
Addis Ababa 19
Andorra la Vella 19
Brooklyn 19
Kampala 19
Mamoudzou 19
Vientiane 19
Antananarivo 18
Conakry 18
Cotonou 18
Dakar 18
Kigali 18
Lilongwe 18
Lima 18
Lusaka 18
Tirana 18
Dushanbe 17
Frankfurt am Main 17
Guayaquil 17
Maputo 17
Ouagadougou 17
Quito 17
Tripoli 17
Niamey 16
Norwalk 16
Rome 16
Willemstad 16
Yerevan 16
Bridgetown 15
Djibouti 15
Johannesburg 15
Nairobi 15
Noumea 15
Praia 15
Totale 9.018
Nome #
Binding and Uptake into Human Hepatocellular Carcinoma Cells of Peptide-Functionalized Gold Nanoparticles 272
PreS1 peptide-functionalized gold nanostructures with SERRS tags for efficient liver cancer cell targeting 244
SCCA1 is associated to poor prognosis in esophageal cancer through immune surveillance impairment and reduced chemosensitivity 239
APC I1307K mutations and forkhead box gene (FOXO1A): another piece of an interesting correlation. 206
Galad Score as a Prognostic Marker for Patients with Hepatocellular Carcinoma 196
SerpinB3 and Yap Interplay Increases Myc Oncogenic Activity 190
A comparison of a moderate with moderate-high intensity oral anticoagulant treatment in patients with mechanical heart valve prostheses 186
SERPINB3 delays glomerulonephritis and attenuates the lupus-like disease in lupus murine models by inducing a more tolerogenic immune phenotype 185
Analytical validation of a Biochip prototype for integrated analysis of AFP-IgM and SCCA-IgM serum biomarkers in patients with liver cirrhosis and hepatocellular carcinoma 183
1-Piperidine Propionic Acid Protects from Septic Shock Through Protease Receptor 2 Inhibition 181
The molecular signature of impaired diabetic wound healing identifies serpinB3 as a healing biomarker. 171
Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. 170
ANTIPHOSPHOLIPID ANTIBODIES ARE NOT PRESENT IN THE MEMBRANE OF GEL-FILTERED PLATELETS OF PATIENTS WITH IGG ANTICARDIOLIPIN ANTIBODIES, LUPUS ANTICOAGULANT AND THROMBOSIS 165
Exogenous Administration of SERPINB3 Inhibits Cell Reprogramming 165
Serum Squamous Cell Carcinoma Antigen-Immunoglobulin M complex levels predict survival in patients with cirrhosis 164
A comparison between six- and four-week intervals in surveillance of oral anticoagulant treatment 163
Squamous cell carcinoma antigen-1 (SERPINB3) polymorphism in chronic liver disease 160
Squamous Cellular Carcinoma Antigen Serum Determination as a Biomarker of Barrett Esophagus and Esophageal Cancer: A Phase III Study 160
Squamous cell carcinoma antigen-IgM (SCCA-IgM) is associated with interstitial lung disease in systemic sclerosis 160
Role of squamous cell carcinoma antigen-1 on liver cells after partial hepatectomy in transgenic mice. 158
Hypoxia up-regulates SERPINB3 through HIF-2α in human liver cancer cells. 155
SQUAMOUS CELL CARCINOMA ANTIGEN- IMMUNOGLOBULIN M (SCCA-IGM) AS BIOMARKER IN LIVER DISEASE: BIOLOGICAL ASPECTS AND CLINICAL APPLICATIONS 154
Squamous cell carcinoma antigen-IgM is associated with hepatocellular carcinoma in patients with cirrhosis: A prospective study 152
Use of a new silica clotting time for diagnosing lupus anticoagulant in patients who meet the clinical criteria for antiphospholipid syndrome 151
SerpinB3 promotes pro-fibrogenic responses in activated hepatic stellate cells 151
Serpinb3 is overexpressed in the liver in presence of iron overload 147
A two-step coagulation test to identify antibeta-glycoprotein I lupus anticoagulants 145
HCV genotype 3 and squamous cell carcinoma antigen (SCCA)-IgM are independently associated with histological features of NASH in HCV-infected patients 144
A comparison of lupus anticoagulant-positive patients with clinical picture of Antiphospholipid syndrome and those without 143
A simple scheme to initiate oral anticoagulant treatment in outpatients with nonrheumatic atrial fibrillation 143
Immunosuppressive treatment in a heart transplantation candidate with antiphospholipid syndrome 142
Detection of high levels of Survivin-immunoglobulin M immune complex in sera from hepatitis C virus infected patients with cirrhosis. 142
BINDING OF AUTOIMMUNE CARDIOLIPIN-REACTIVE ANTIBODIES TO HEPARIN - A MECHANISM OF THROMBOSIS 139
Tumour-specific induction of immune complexes: DCP-IgM in hepatocellular carcinoma 138
Purification of anticardiolipin and lupus anticoagulant activities by using cardiolipin immobilized on agarose beads. 137
Monitoring SCCA-IgM complexes in serum predicts liver disease progression in patients with chronic hepatitis 137
[Anti-beta(2) glycoprotein I beta(2) glycoprotein I] immune complexes in patients with antiphospholipid syndrome and other autoimmune diseases 135
Engineered EVs for oxidative stress protection 133
HEPATIC PROGENITOR CELLS OVEREXPRESS SERPINB3 IN A MOUSE MODEL OF FULMINANT HEPATITIS 132
Some patients with antiphospholipid syndrome express hitherto undescribed antibodies to cardiolipin-binding proteins 131
Autoimmune antiphospholipid antibodies are directed against a cryptic epitope expressed when β2-glycoprotein I is bound to a suitable surface 130
The protease-inhibitor SerpinB3 as a critical modulator of the stem-like subset in human cholangiocarcinoma 130
Immunosuppressive treatment in a heart transplantation candidate with antiphospholipid syndrome. 129
Relapse after direct-acting antivirals (DAAs) in cirrhotic patients with hepatitis C is highly related to development of liver cancer 127
The Protease Activated Receptor 2 - CCAAT/Enhancer-Binding Protein beta - SerpinB3 axis inhibition as a novel strategy for the treatment of Non-Alcoholic Steatohepatitis 126
Accuracy of a portable prothrombin time monitor (Coagucheck) in patients on chronic anticoagulant therapy: a prospective multicenter study 126
PURIFICATION OF ANTICARDIOLIPIN AND LUPUS ANTICOAGULANT ACTIVITIES BY USING CARDIOLIPIN IMMOBILIZED ON AGAROSE BEADS 125
SERPINB3 is associated with longer survival in transgenic mice. 125
1-Piperidine Propionic Acid as an Allosteric Inhibitor of Protease Activated Receptor-2 124
[IgG anti-beta 2-glycoprotein I beta 2-glycoprotein I] immune complexes in patients with antiphospholipid (aPL) syndrome 124
Experimental validation of specificity of the squamous cell carcinoma antigen-immunoglobulin M (SCCA-IgM) assay in patients with cirrhosis 124
Hepatic progenitor cells overexpress SERPINB3 in a mouse model of fulminant hepatitis 123
SERPINB3 AS A PRO-INFLAMMATORY MEDIATOR IN THE PROGRESSION OF EXPERIMENTAL NON-ALCOHOLIC FATTY LIVER DISEASE. 121
COMBINING SCCA-IGM AND AFP-IGM LEVELS INCREASES ACCURACY OF HEPATOCELLULAR CARCINOMA DETECTION 119
Monitoring SCCA-IgM complex predicts liver disease progression in patients with chronic hepatitis and cirrhosis 119
Increased antiprotease activity of the SerpinB3 polymorphic variant SCCA-PD 118
The polymorphic variant of SerpinB3 (SerpinB3-PD) is associated with faster cirrhosis decompensation 117
RUOLO DI SERPINB3 ELLA PROGRESSIONE DELLA MALATTIA EPATICA 116
Low intensity warfarin therapy. 115
CARATTERIZZAZIONE BIOLOGICA E FUNZIONE DELLA NUOVA ISOFORMA SCCA-PD 115
Serum and bile squamous cell carcinoma antigen 1 (SCCA1) detection: a new diagnostic approach in patients with perihilar cholangiocarcinoma (pCCA) 115
SCCA-IGM USEFULNESS TO MONITOR PATIENTS WITH CIRRHOSIS IS NOT AFFECTED BY INTERFERING IGM'S 114
Development of a novel diagnostic algorithm to predict NASH in HCV-positive patients 114
Cellule progenitrici epatiche esprimono SERPINB3b in un modello murino di epatite fulminante 113
REVERSAL OF EXCESSIVE EFFECT OF REGULAR ANTICOAGULATION - LOW ORAL DOSE OF PHYTONADIONE (VITAMIN-K1) COMPARED WITH WARFARIN DISCONTINUATION 111
Anti phospholipid antibody ELISAs: Survey on the performance of clinical laboratories assessed by using lyophilized affinity-purifled IgG with anticardiolipin and anti-beta 2-glycoprotein I activity 111
Modulazione dei livelli di IL-6 nella rigenerazione epatica da parte di SERPINB3 ed estrogeni. Analisi in un modello di topo transgenico 110
Modeling the time-related fluctuations of AFP and PIVKA-II serum levels in patients with cirrhosis undergoing surveillance for hepatocellular carcinoma 110
SerpinB3 Upregulates Low-Density Lipoprotein Receptor-Related Protein (LRP) Family Members, Leading to Wnt Signaling Activation and Increased Cell Survival and Invasiveness 110
SERPINB3 modulates TGF-beta expression in chronic liver disease. 109
SerpinB3/Protease Activated Receptor-2 Axis Is Essential for SARS CoV-2 Infection 107
HPYPOXYA UP-REGULATES SERPINB3 IN HEPATIC CANCER CELLS: A HIF-2a ASSOCIATED EVENT RELATED TO INVASIVENESS AND EPITHELIAL TO MESENCHYMAL TRANSITION 107
HYPOXIA UP-REGULATES SERPINB3 IN HEPG2 CELLS: A REDOX SENSITIVE EVENT RELATED TOEPITHELIAL TO MESENCHYMAL TRANSITIONAND INVASIVENESS 106
Sex dependent IL-6 deregulation by SERPINB3 in a transgenic mouse model 105
POLIMORFISMO DI SCCA (SQUAMOUS CELL CARCINOMA ANTIGEN) E PROGRESSIONE DELLA MALATTIA EPATICA NELL’INFEZIOE HCV 105
CHARACTERIZATION OF SCCA-1(SERPINB3) ISOFORMS IN HEPATOCELLULAR CARCINOMA 104
Bile detection of squamous cell carcinoma antigen (SCCA) in extrahepatic cholangiocarcinoma 103
SQUAMOUS CELL CARCINOMA ANTIGEN (SCCA) ENHANCES LIVER REGENERATION AFTER PARTIAL HEPATECTOMY 103
HFE, TGF-BETA1 AND SQUAMOUS CELL CARCNOMA ANTIGEN-1 POLYMORPHISMS AND LIVER DISEASE STAGE IN CHRONIC HCV INFECTION 101
Epitope-Specific Anti-SerpinB3 Antibodies for SerpinB3 Recognition and Biological Activity Inhibition 100
Lupus anticoagulant (LA) testing: performance of clinical laboratories assessed by a national survey using lyophilized affinity-purified immunoglobulin with LA activity 100
Impact of etiology of chronic liver disease on hepatocellular carcinoma biomarkers 100
Autoimmune antiphospholipid antibodies: What is their true target? 99
Effect of anti-beta-2-glycoprotein I Lupus Anticoagulants on fibrin polymerization and fibrinolysis 99
COMPORTAMENTO DI SCCA-IgM NEL SIERO DI BAMBINI HBeAg POSITIVI SEGUITI NEL TEMPO 99
OVEREXPRESSION OF SERPINB3 IN HEPATIC PROGENITOR CELLS IN A MOUSE MODEL OF ACUTE LIVER INJURY 98
SerpinB3 administration protects liver against ischemia-reperfusion injury 97
Semisolid Wet Sol–Gel Silica/Hydroxypropyl Methyl Cellulose Formulation for Slow Release of Serpin B3 Promotes Wound Healing In Vivo 97
Mechanical prosthetic heart valve thrombosis despite optimal anticoagulation in a patient with congenital thrombophilia (factor V Leiden) 97
LRP-1 BINDS SERPINB3 AND MEDIATES ITS MIGRATORY ACTIVITY 94
SCCA1-IGM AND SCCA2-IGM COMPARED WITH TOTAL SCCA-IGM FOR DIAGNOSIS OF HEPATOCELLULAR CARCINOMA 93
Utilization of dilute Russell's viper venom time to detect autoantibodies against beta 2-glycoprotein I which express anticoagulant activity in the presence but not in the absence of exogenous phospholipids. 92
Assessment of patient capability to self-adjust oral anticoagulant dose: a multicenter study on home use of a portable prothombin time monitor (Coagucheck) 92
MATRIX METALLOPROTEINASE 9 (MMP9)-IgM COMPLEX: AN EMERGING NOVEL BIOMARKER IN COLORECTAL CANCER 91
Oncostatin M is overexpressed in NASH-related hepatocellular carcinoma and promotes cancer cell invasiveness and angiogenesis 90
SEX DEPENDENT IL-6 DEREGULATION BY SERPINB3 IN A TRANSGENIC MOUSE MODEL 89
CIRCULATING SURVIVIN-IGM IS A NOVEL CANDIDATE BIOMARKER OF CIRRHOSIS AND INCREASES WITH CHILD SCORE IN PATIENTS AFFECTED BY LIVER DISEASES 89
Overexpression of SERPINB3 in hepatic progenitor cells in a mouse model of acute liver injury 88
The risk of overdiagnosis of antiphospholipid syndrome 86
EVALUATION OF THE ANALYTICAL SPECIFICITY OF SCCA-IGM ASSAY FOR MONITORING PATIENTS WITH CIRRHOSIS 86
Totale 13.056
Categoria #
all - tutte 45.374
article - articoli 38.531
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 481
Totale 84.386


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021868 0 0 0 0 21 98 25 88 180 180 140 136
2021/20221.185 23 155 106 103 58 80 61 106 77 19 129 268
2022/20231.159 245 122 61 115 179 168 6 72 131 11 35 14
2023/2024571 22 99 66 37 44 79 38 27 12 17 58 72
2024/20252.752 18 257 118 107 290 78 142 193 219 115 485 730
2025/20264.814 477 886 1.463 1.429 559 0 0 0 0 0 0 0
Totale 14.801